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Background: Themembrane topology and the role of certain cysteines in human vitamin K epoxide reductase (VKOR) are
disputed.
Results: VKOR has three transmembrane domains, and only the active site cysteines are required for function.
Conclusion: Despite similarities, VKOR and its bacterial homologues (VKORHs) have different topologies and reaction
mechanisms.
Significance: The VKOR does not employ the intramolecular electron transfer pathway proposed for VKORH.
Vitamin K epoxide reductase (VKOR) is essential for the pro-
ductionof reduced vitaminK that is required formodificationof
vitamin K-dependent proteins. Three- and four-transmem-
brane domain (TMD) topology models have been proposed for
VKOR. They are based on in vitro glycosylation mapping of the
human enzyme and the crystal structure of a bacterial (Syn-
echococcus) homologue, respectively. These two models place
the functionally disputed conserved loop cysteines, Cys-43 and
Cys-51, on different sides of the endoplasmic reticulum (ER)
membrane. In this study, we fused green fluorescent protein to
theNorC terminus of humanVKOR, expressed these fusions in
HEK293 cells, and examined their topologies by fluorescence
protease protection assays. Our results show that the N termi-
nus of VKOR resides in the ER lumen, whereas its C terminus is
in the cytoplasm. Selectivemodification of cysteines by polyeth-
ylene glycol maleimide confirms the cytoplasmic location of the
conserved loop cysteines. Both results support a three-TMD
model of VKOR. Interestingly, human VKOR can be changed to
a four-TMD molecule by mutating the charged residues flank-
ing the first TMD. Cell-based activity assays show that this four-
TMDmolecule is fully active. Furthermore, the conserved loop
cysteines, which are essential for intramolecular electron trans-
fer in the bacterial VKOR homologue, are not required for
humanVKORwhether they are located in the cytoplasm (three-
TMD molecule) or the ER lumen (four-TMD molecule). Our
results confirm that human VKOR is a three-TMD protein.
Moreover, the conserved loop cysteines apparently play differ-
ent roles in human VKOR and in its bacterial homologues.
Vitamin K epoxide reductase (VKOR)2 is a 163-amino acid
polytopic membrane protein of the endoplasmic reticulum
(ER) (1, 2). It is responsible for the conversion of vitamin K
2,3-epoxide (KO) into vitamin K and is highly sensitive to inhi-
bition by coumarin drugs, such aswarfarin, themost commonly
prescribed oral anticoagulant (3).Warfarin inhibition of VKOR
reduces the availability of vitamin K hydroquinone (KH2),
which is a cofactor for -glutamyl carboxylase. -Glutamyl car-
boxylase catalyzes the functionally critical post-translational
modification of a family of vitamin K-dependent proteins
involved in blood coagulation, bone homeostasis, signal trans-
duction, and cell proliferation (4, 5). Deficiency of KH2 causes
partial carboxylation or noncarboxylation of vitamin K-depen-
dent proteins resulting in defects primarily of blood coagula-
tion (4, 6, 7). Concomitant with carboxylation, KH2 is oxidized
to KO, which must be converted back to KH2 by VKOR and an
as yet unidentified vitamin K reductase for the carboxylation
reaction to continue.
Based on a chemical model study, a reaction mechanism for
converting KO to vitamin K by VKOR was proposed by Silver-
man (8). A quantum chemical study of the reactionmechanism
of KO reduction by VKOR supports and extends the Silverman
mechanism (9). This study predicts that once a key disulfide
bond of VKOR is broken, the reaction is energetically favorable.
Experimental data supporting the proposed chemical model
comes from a study of VKOR activity with a variety of thiol
compounds (10). It has been proposed that the thioredoxin
(Trx) family proteins serve as the physiological reductant for
VKOR (11–14); however, this hypothesis has been questioned
(15). Currently, the physiological reductant of VKOR remains
unknown.
With the identification of the gene encoding human VKOR
(1, 2), it became possible to study its structure-function rela-
tionship at themolecular level. Site-directedmutagenesis stud-
ies confirmed that two conserved cysteines, Cys-132 and Cys-
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135, comprise the active site redox center (CXXC) in VKOR
(16–18). Although the identity of the active site residues is
clear, reports of the function of the other pair of conserved
cysteines, Cys-43 and Cys-51 (the loop cysteines), do not allow
a consistent interpretation for their role. Results with Trx/Trx
reductase suggest that a redox protein transfers electrons to the
loop cysteines, which in turn reduces the membrane-embed-
ded active site Cys-132–Cys-135 disulfide bond to activate
VKOR (19). However, a VKORmutantwith both loop cysteines
changed to alanine has wild-type enzyme activity with dithio-
threitol (DTT) as reductant, suggesting that the loop cysteines
are not essential for VKOR activity (16, 18). We extended this
observation to an in vivo activity assay system where VKOR
uses the endogenous reductant in the native milieu rather than
DTT (20). Our in vivo results support the conclusion that the
loop cysteines are not required for VKOR activity.
To better understand the structure-function relationships of
VKOR, we have determined the membrane topology of human
VKOR by in vitro translation/co-translocation (21). Our results
suggest that VKOR is a three-transmembrane domain (TMD)
protein with its N terminus located in the ER lumen and C
terminus in the cytoplasm (Fig. 1A). In this model, the active
site cysteines (Cys-132 and Cys-135) are located at the N ter-
minus of the third TMD facing the ER lumen. However, this
topology places the conserved loop cysteines Cys-43 and
Cys-51 in the cytoplasm, on the opposite side of the ER mem-
brane from the active site cysteines. Our three-TMD model is
consistent with the other results suggesting that the loop cys-
teines are not directly involved in VKOR activity (16, 18, 20).
VKOR appears to be a member of a large family of homo-
logues (VKORHs) widely distributed among vertebrates, inver-
tebrates, plants, bacteria, and archaea (22). In bacteria,
VKORHs are present in strains lacking the cytoplasmic mem-
brane proteinDsbB that is important for protein oxidative fold-
ing in the periplasm (23). The functional similarity between
bacterial VKORHs and DsbB is shown by the observation that
bacterial VKORHs can complement DsbB to restore DsbA-de-
pendent disulfide bond formation of secreted proteins in Esch-
erichia coli (23–25). Moreover, the crystal structure of a bacte-
rial VKORH from Synechococcus reveals a four-TMD structure
of the VKOR domain that is similar to DsbB (26). Based on this
structure, a four-TMD topology model for human VKOR has
been proposed (Fig. 1B). In addition, an intramolecular electron
transfer pathway between the two pairs of conserved cysteines,
similar to that of DsbB, has been proposed for the bacterial
VKORHs as well as for mammalian VKOR (26, 27). These
results raise the question as to whether the bacterial enzymes
and the mammalian ones have the same membrane topology
and whether they employ different mechanisms to regenerate
the active site cysteines.
To further clarify the membrane topology and the reaction
mechanism of human VKOR, we employed independent bio-
chemical techniques, fluorescence protease protection (FPP)
assay (28), and selectivemodification of the VKOR endogenous
cysteines by polyethylene glycol maleimide (PEG-MAL) (29) to
probe the membrane topology of the intact VKORmolecule in
mammalian cells. We used our recently established cell-based
activity assay to examine the role of the conserved loop cys-
teines in VKOR. Our results support the three-TMD model of
human VKOR and suggest that intramolecular electron trans-
fer between the loop cysteines and the active site cysteines of
VKOR is not necessary for its function.
EXPERIMENTAL PROCEDURES
Materials—Vitamin K1, warfarin, digitonin, and trypsin
(bovine pancreas) were obtained from Sigma. Methoxy-poly-
ethylene glycol maleimide, molecular weight 5000 (mPEG-
MAL-5000), was purchased from Nektar (Huntsville, AL) and
Laysan Bio. Inc. (Arab, AL). Luciferase substrate coelenterazine
was fromNanoLight Technology (Pinetop, AZ). Complete pro-
tease inhibitor mixture tablets and 2,2-azino-bis(3-ethylben-
zothiazoline-6-sulfonic acid) solution for ELISA were pur-
chased from Roche Applied Science. Immobilon-P PVDF
membrane was from Millipore Corp. (Bedford, MA). ECL
Western blotting detection reagents were fromGEHealthcare.
Mammalian expression vector pIRESpuro3, Xfect transfection
reagent, and green fluorescence protein (GFP) containing vec-
tor pEGFP-N1 were from Clontech. Cytochrome b5 cDNAwas
from Open Biosystems (Huntsville, AL). The gene encoding
asialoglycoprotein receptor (ASGPR) subunit H1 was kindly
provided byDr.Martin Spiess (University of Basel, Switzerland)
(30). Restriction enzymes and peptide:N-glycosidase F were
from New England Biolabs (Ipswich, MA). QuikChange site-
directed mutagenesis kit was from Stratagene (La Jolla, CA).
HEK293 cell line was from the ATCC (Manassas, VA). Mam-
malian expression vector pBudCE4.1, all cell culturemedia, and
oligonucleotide primers were from Invitrogen.Mouse anti-car-
boxylated FIX gla domain monoclonal antibody was a gift from
GlaxoSmithKline (Philadelphia) and Green Mountain Anti-
bodies (Burlington, VT) (31, 32). Horseradish peroxidase-con-
jugated affinity-purified sheep anti-human protein C IgG was
from Affinity Biologicals, Inc. (Ancaster, Ontario, Canada).
Anti-HPC4 monoclonal antibody was from Dr. Charles T.
Esmon (Oklahoma Medical Research Foundation, Oklahoma
City, OK). Lab-Tek II chambered cover glasses (4-well) were
from Nalge Nunc International (Rochester, NY). The 96-well
enzyme immunoassay/radioimmunoassay high binding flat
bottom plates were purchased from Corning Inc. (Corning,
NY).
DNA Manipulations and Plasmid Constructions—Mamma-
lian expression vector pIRESpuro3 was used as the basic clon-
ing and expression vector. For the FPP assay, GFP was fused to
the N or C terminus of the target protein with a 30-amino acid
flexible linker (GGSGG)6 between the two entities as described
previously (33). The linker was generated by the annealing of
four oligonucleotides with a BamHI and a BglII site flanking the
5 and the 3 end, respectively. The annealed fragment was
cloned into the BamHI site of the pIRESpuro3 vector. The BglII
site at the 3 end of the linker introduces an arginine residue
that is susceptible to trypsin cleavage in the FPP assay. For the
N-terminal GFP fusion, the gene encoding GFP was amplified
by PCR using a 5 primer containing the Kozak sequence
flanked by an EcoRI site and a 3 primer flanked by a BamHI site
without the stop codon. The PCR product was cloned into the
pIRESpuro3 vectorwith the (GGSGG)6 linker by EcoRI/BamHI
to yield pIRESpuro3-GFP-N. The gene encoding the target pro-
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tein was amplified by PCR using primers flanked with an NotI
site at both ends and subcloned into pIRESpuro3-GFP-N at its
NotI site. For the C-terminal GFP fusion, the gene encoding
GFP was amplified by PCR using primers flanked with NotI
sites at both ends. The PCR product was cloned into the NotI
site of the pIRESpuro3 vectorwith the (GGSGG)6 linker to yield
pIRESpuro3-GFP-C. The gene encoding the target protein was
amplified by PCR using a 5 primer flanked with an EcoRI site
with the Kozak sequence and a 3 primer flanked with a BamHI
site (BglII for VKOR)without the stop codon. The PCRproduct
was subcloned into pIRESpuro3-GFP-C by EcoRI/BamHI.
For the FPP control assays, we used the single-TMD protein
ASGPR and the tail-anchored protein CYB5 as model proteins.
Both proteins are type II integral membrane proteins with the
N terminus located in the cytoplasm and C terminus in the ER
lumen.We replaced the cytoplasmic N-terminal heme-binding
domain (residues 1–90) of CYB5 (34) and the lumenal C-termi-
nal carbohydrate recognition domain of ASGPR (residues 147–
290) (35), respectively, with GFP (Fig. 2B).
Site-directed mutagenesis was performed by a QuikChange
kit to create cysteine mutations or change the charged residues
in VKOR according to the manufacturer’s instructions (Strat-
agene). For Western blot detection, an HPC4 tag (EDQVD-
PRLIDGK)was introduced at the C terminus of the VKORwith
its ER retention sequence (KAKRH). As an internal control for
our cell-based VKOR activity assay,Metridia luciferase cDNA
was cloned into one of the multicloning sites of the dual mam-
malian expression vector pBudCE4.1 to yield pBudCE4.1-
Met.Luc. All the VKOR constructs were subcloned into a dif-
ferent multicloning site of pBudCE4.1-Met.Luc. All the VKOR
constructs for the in vivo cell-based activity assay have a warfa-
rin-resistant mutation of Y139F. The nucleotide sequences of
all the constructs were verified by sequencing at Eton Biosci-
ence Inc. (Research Triangle Park, NC).
FPP Assay—FPP assay was performed as described previ-
ously (28) with minor modifications. HEK293 cells were sub-
cultured into chambered cover glass with complete growth
medium to yield80% confluency at the time for the FPP assay.
Cells were transiently transfected with pIRESpuro3 plasmid
DNA containing the GFP-tagged target protein using transfec-
tion reagent Xfect according to the manufacturer’s protocol.
Forty eight hours post-transfection, cells were washed three
times for 1 min each with KHM buffer (110 mM potassium
acetate, 2 mMMgCl2, and 20 mMHEPES, pH 7.2) at room tem-
perature. After washing, 200 l of KHM buffer was added to
each chamber before placing the chambered cover glass on the
microscope stage. Confocal microscopy was performed on a
Zeiss LSM710 confocal laser scanning microscope (Carl Zeiss
Microimaging, Thornwood,NY). Imageswere collected using a
40/1.2NA C-Apochromat objective lens. Visualization of the
GFP was achieved by use of a 488 nm argon laser line for exci-
tation, and the detector was set to collect emission at 493–530
nm.Wecollected a time series of images of the chosen cell using
ZEN software. Successive images were collected at an interval
of 30 s. After the fourth image was taken, 200 l of KHMbuffer
containing 0.2 mM digitonin was added to the chamber (final
concentration is 0.1 mM) to selectively permeabilize the plasma
membrane. Two minutes after the addition of digitonin (i.e.
after the 8th imagewas taken), 400l of KHMbuffer containing
2 M trypsin was gradually added to the chamber to elicit pro-
tease digestion of GFP in the cytoplasm. The essential factor
that affects the FPP assay is the concentration of digitonin. To
determine the effective digitonin concentration for permeabi-
lizing the plasma membrane, increasing concentrations of dig-
itonin in KHM buffer were added to HEK293 cells transiently
expressing GFP. The lowest digitonin concentration (0.1 mM)
resulting in the disappearance of the GFP signal within 60 s was
chosen (28). To compare changes in fluorescence intensity
post-treatment, instrument software was used to define and
mark areas of interest within cells. Mean pixel intensity within
the area of interest was used as a marker for comparison.
Selective Modification of the Endogenous VKOR Cysteines by
mPEG-MAL—Selective modification of the cysteines of VKOR
by mPEG-MAL was performed as described previously (29)
with additional modifications. VKOR or VKOR C43A/C51A
mutant with a C-terminal HPC4 tag was transiently expressed
in HEK293 cells in a 6-well plate. Forty eight hours post-trans-
fection, cells were washed twice in situ with PBS, pH 6.8, and
detached by pipetting. Cells were harvested by centrifugation,
and cell pellets were resuspended in PBS. Samples were ali-
quoted into three tubes; one was a control with no detergent,
and the other two were incubated with 0.1 mM digitonin or 1%
Triton X-100 in the presence of a protease inhibitormixture on
ice for 10 min. The digitonin concentration used for selectively
permeabilizing the plasma membrane was as described above
with the GFP test in the FPP assay. Freshly prepared mPEG-
MAL-5000 solution was added to each sample to a final con-
centration of 20mM and incubated on ice for 30min. The reac-
tion was stopped by adding DTT to a final concentration of 50
mM, followed by SDS loading buffer for SDS-PAGE and West-
ern blot detection.
Cell-based VKOR Activity Assay—The in vivo activity assay
for VKOR and its variants used in this study was performed
according to our recently established cell-based assay (36) with
minor modifications. It is based on the ability of VKOR or its
homologue to convert KO to vitamin K in mammalian cells to
support the carboxylation of a reporter protein. The reporter
chimera protein FIXgla-PC, which has the gla domain of factor
IX replacing the gla domain of protein C, was stably expressed
in HEK293 cells (FIXgla-PC/HEK293). Plasmid DNA of
pBudCE4.1-Met.Luc containing the cDNA of wild-type or
mutant VKOR was transiently expressed in FIXgla-PC/
HEK293 cells in a 24-well plate usingXfect transfection reagent
according to the manufacturer’s instructions (Clontech). Five
hours post-transfection, the transfectionmediumwas replaced
by a complete cell culture medium containing 5 M KO with 4
Mwarfarin. The cell culturemediumwas collected after a 48-h
incubation and directly used for ELISA to determine the level of
carboxylated reporter protein (FIXgla-PC) and for the lucifer-
ase activity assay to normalize for the transfection efficiency
(20). Because endogenous VKOR in HEK293 cells can effi-
ciently carboxylate the reporter protein (250–300 ng/ml car-
boxylated FIXgla-PC in the cell culturemedium), 4Mwarfarin
was used in all assays to inhibit the endogenous VKOR activity.
Warfarin reduced carboxylation of reporter protein to
extremely low background levels (5–10 ng/ml carboxylated
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FIXgla-PC). For this reason, all theVKORmolecules used in the
cell-based activity assay have the Y139F warfarin-resistant
mutation. Therefore, wild-type VKOR activity in this study
refers to the activity of VKOR-Y139F warfarin-resistant
mutant.
RESULTS
Localization of the N and C Termini of Human VKOR in
HEK293 Cells by FPP Assay—The two proposed membrane
topology models for human VKOR agree with each other in
terms of the location of the C terminus but are in conflict as to
the location of theN terminus and the conserved loop cysteines
(Cys-43 and Cys-51) (Fig. 1). To clarify this disagreement, we
fusedGFP to either theNorC terminus ofVKORand thenused
the FPP cell assays to probe the location of the two termini in
intact VKOR molecules in mammalian HEK293 by confocal
microscopy. These chimeric proteins were transiently
expressed in HEK293 cells, and the plasma membranes were
selectively disrupted by digitonin followed by the addition of
trypsin. Results show that when GFP is fused to the N terminus
of VKOR (GFP-VKOR), it is protected from trypsin digestion
(Fig. 2A). However, the C-terminal GFP fusion of VKOR
(VKOR-GFP) is susceptible to protease digestion in digitonin-
permeabilized cells. This result suggests that the N terminus of
VKOR is located in the ER lumen, and the C terminus is located
in the cytoplasm. Control experiments were performed by fus-
ing GFP to either the cytoplasmic or lumenal terminus of the
single TMDmodel proteins ASGPR andCYB5 (Fig. 2,B andC).
These results agree with our previous in vitro results that sug-
gest that VKOR is a three-TMD protein (21).
To examine the enzymatic activity of the GFP tagged VKOR
molecules, we used our recently established cell-based activity
assay (36). Fig. 3 shows that the fusion of GFP, which is approx-
imately twice the size of VKOR, to VKOR decreased its activity
to about 50% compared with the wild-type enzyme. This result
demonstrates that theGFP-taggedVKORused in the FPP assay
for themembrane topology study has passed ER quality control
and is enzymatically active.
SelectiveModification of the Endogenous Cysteine Residues in
VKOR bymPEG-MAL—Another difference between the three-
and four-TMDmodels for VKOR is the location of the cysteine
residues in terms of the ER membrane (Fig. 1). In the three-
TMD model, the conserved loop cysteines Cys-43 and Cys-51
along with Cys-85 and Cys-96 are located in the cytoplasm. In
contrast, none of the cysteine residues are located in the cyto-
plasm in the four-TMD model. To clarify these two topology
models, we used a membrane-impermeable sulfhydryl modifi-
cation reagent mPEG-MAL-5000 to selectively modify the cys-
teines of VKOR in HEK293 cells. Modification of each cysteine
by mPEG-MAL-5000 is expected to increase the apparent
molecular mass of VKOR by 10 kDa (29), which can be easily
separated by SDS-PAGE and visualized byWestern blot analy-
sis. In this experiment, we transiently expressed HPC4-tagged
VKOR in HEK293 cells. The cells were again treated with digi-
tonin which preferentially permeabilizes the cell membrane
over the ER membrane. Thus, the modification reagent should
react only with the cysteine residues exposed to the cytoplasm.
If VKOR is a four-TMD protein, none of the seven endogenous
cysteines should be available to react withmPEG-MALbecause
they would be found within the protected ER membrane or
lumen.
Fig. 4A shows thatwhen cells expressingwild-typeVKORare
selectively permeabilized by digitonin and modified by mPEG-
MAL-5000, two PEG-labeled protein bands with a higher
molecular weight are observed (Fig. 4A, lane 2). This result
suggests that at least two cysteine residues of VKOR are located
in the cytoplasm. When both the plasma and ER membranes
are disrupted with Triton X-100, at least five PEG-modified
protein bands are observed, and most of the VKOR molecules
have two or three mPEG-MAL modifications (Fig. 4A, lane 3).
Because the PEGmolecule is large, when two cysteines are close
to each other (for example cysteine 132 and 135), they may not
be modified efficiently. In addition, when more cysteines are
modified, itmay decrease the transfer efficiency of themodified
protein from the gel to the membrane. Our result suggests that
FIGURE 1. Proposed membrane topology models of human VKOR. A, three-TMD topology model of human VKOR based on in vitro translation/co-translo-
cation (21). The N terminus of VKOR is located in ER lumen and the C terminus in the cytoplasm. Conserved active site and loop cysteines are indicated by
gradient filling of the circle, and they are located on the opposite side of ER membrane. The positively charged residues flanking TMD1 are shaded in gray. B,
proposed four-TMD topology model of human VKOR based on the crystal structure of a bacterial VKOR homologue (26). In this model, both the N and C
terminus are located in the cytoplasm. Conserved active site cysteines and the loop cysteines are located in the same side of the ER membrane.
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at least five of the seven cysteines in VKOR can be modified
simultaneously bymPEG-MALwhen the plasma and ERmem-
brane were permeabilized. These results agree with the above
FFP assay and again are consistent with VKOR being a three-
TMD protein.
In the three-TMDmodel, of the four cysteines located in the
cytoplasm, Cys-43 and Cys-51 are located in a hydrophilic
region, and Cys-85 and Cys-96 reside in a hydrophobic region
of VKOR (Fig. 4B). Therefore, we suspected that the two cys-
teines modified under ER intact conditions (Fig. 4A, lane 2) are
the cytoplasmic hydrophilic region loop cysteines Cys-43 and
Cys-51. To test this hypothesis, we mutated both cysteines to
alanine and repeated the mPEG-MAL modification. When
Cys-43 and Cys-51 were mutated, under ER intact conditions,
the two PEG protein adducts were significantly reduced in the
mutant enzyme as compared with the wild-type enzyme (Fig.
4A, lane 5). In addition, the 4- and 5-fold PEG-modified forms
also dramatically decreased when the cells were treated with
Triton X-100 (Fig. 4A, lane 6). We demonstrated previously
that the VKOR mutant C43A/C51A has almost wild-type
enzyme activity, indicating it folds correctly and functions nor-
mally (16, 20). Together our results suggest that the conserved
loop cysteines Cys-43 and Cys-51 are located in the cytoplasm
and again support the three-TMDmodel of VKOR.
VKOR Topology Can Be Changed by Mutating the Charged
Residues Flanking TMD1—Our results thus far suggest that,
consistent with our previous conclusion, VKOR is a three-
TMD protein. The orientation of the first TMD in the three-
TMDmodel agrees with the “positive inside rule” (37). A num-
ber of positively charged residues are found after the TMD1
that are located on the cytoplasmic side of the ER membrane
(inside). To test the contribution of the charged residues flank-
ing TMD1 to VKOR topology, we removed four positively
charged residues at the C terminus of TMD1 by making the
following mutations: K30L, R33G, R35G, and R37G. We also
added three positive charged residues to the N terminus of
VKOR by making the mutations of G6R, S7R, and G9R. The
topology prediction program TMHMM predicts three TMDs
FIGURE 2. Localization of the N and C termini of VKOR in HEK293 cells by fluorescence protease protection assay. A, FPP assay of GFP fusions of human
VKOR. GFP-tagged VKOR fusions were transiently expressed in HEK293 cells. Forty eight hours post-transfection, cells were selectively permeabilized with 0.1
mM digitonin. Then trypsin was added, and images were collected at the indicated time intervals. B, schematic representation of the single TMD model proteins
(ASGPR and CYB5) and their GFP fusions. The solid bars indicate the TMD; the gray bars indicate the lumenal carbohydrate recognition domain (CMD) of ASGPR
or the cytoplasmic heme-binding domain (HBD) of CYB5. Dark gray bars indicate the (GGSGG)6 linker between GFP and the model proteins. C, FPP assay of GFP
fusion of the model proteins as described above.
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for wild-type VKOR but four TMDs for the charge mutant
VKOR-CM with both its N and C termini located in the
cytoplasm.
To experimentally test the membrane topology of this
charged residue mutant protein, we repeated the FPP assay by
fusing GFP to either the N or C terminus of the VKOR-CM
mutant. Our result shows that GFP fused to either the N or C
terminus of VKOR-CM is now sensitive to protease digestion
when the cell membrane is disrupted with digitonin (Fig. 5A).
This result indicates that both ends of this mutated VKOR are
located in the cytoplasm. Therefore, themembrane topology of
the mutated protein has been changed to a four-TMD protein.
The sequence 75–97, which we previously demonstrated could
function as a stop-transfer sequence in vitro (21), now appears
to span the membrane as a TMD. Therefore, instead of chang-
ing the topology of the whole protein, the C-terminal half of the
molecule retains the orientation as in the wild-type enzyme.
Compared with the C-terminal tagged GFP, there is an 60-s
delay in the disappearance of the fluorescence signal of the
N-terminal GFP-tagged VKOR-CM. But compared with wild-
type VKOR, the accessibility of the N-terminal GFP tag to pro-
tease digestion is obvious (Fig. 5B) indicating its cytoplasmic
location.
To determine the enzymatic activities of the above mutant
VKOR, we performed our in vivo cell-based activity assay. The
results in Fig. 5C show that VKOR-CM mutant has an even
higher activity than the wild-type enzyme. This experimentally
altered four-TMD human VKOR retains almost full activity
when GFP is fused to the N terminus. The C-terminal GFP
fusion, however, shows significantly decreased activity. Even
this VKOR mutant fusion (VKOR-CM-GFP) has almost the
same activity as the wild-type nonfusion enzyme.
Conserved Loop Cysteines Cys-43 and Cys-51 Are Not
Involved in Intramolecular Electron Transfer—The above
results suggest that human VKOR normally has three TMDs.
This places the conserved loop cysteines Cys-43 and Cys-51 on
the opposite side of the ER membrane from the active site
CXXC. Changing the charged residues flanking TMD1 reverses
the orientation of TMD1 and places the loop cysteines in the ER
lumen. Furthermore, the charge-mutatedVKOR-CMwith four
TMDs appears to be more active than the wild-type enzyme.
One possible reason for the higher activity of VKOR-CM could
be that moving the loop cysteines to the same side (lumenal) of
the ER membrane as the active site CXXC favors the electron
transfer pathway proposed for bacterial VKORH and human
VKOR (19, 26, 27). To test this possibility, we mutated the loop
cysteines (both individually and together) of the VKOR-CM
mutant and tested their activity in our cell-based in vivo activity
assay. Mutation of Cys-43 significantly decreased the VKOR
activity as in the wild-type enzyme (Fig. 6). However, C51A or
the double cysteinemutant (C43A/C51A) had aminor effect on
VKOR activity. In addition, the activity of both the C51A and
the double cysteine mutant (C43A/C51A) of the altered four-
TMD form of VKOR are more active than the wild-type three-
TMD enzyme. These results suggest that the increased activity
in the charged residue mutant VKOR-CM is not due to the
favorable location of the conserved loop cysteine for intramo-
lecular electron transfer.
Sequences Following the Conserved Loop Cysteine Appears
Not to be Involved in the Control Mechanism for VKOR
Activity—The crystal structure of VKOR bacterial homo-
logue revealed a 1/2-helix structure after the second con-
served loop cysteine, Cys-56 (26). According to the sequence
homology, these authors proposed a similar 1/2-helix (resi-
dues Ser-52 to Ser-57) in human VKOR following the second
conserved loop cysteine Cys-51 that forms an amphipathic
lid on the four-helix bundle. They suggested that “the 1/2-
helix must move out of the way, perhaps by sliding parallel to
the plane of the membrane, to allow Cys-56 in the loop to
gain access to Cys-130 of the CXXC motif. In the resting
state, the 1/2-helix would shield the active site, preventing it
from nonselectively oxidizing proteins in the periplasm”
(26). If this hypothesis holds for human VKOR, disruption of
the 1/2-helix should leave the active site of VKOR open and
susceptible to nonselective oxidation. In that case, VKOR
(oxidized form) should be inactive. To test this hypothesis,
we have mutated the conserved residue Val-54, which
resides in the middle of the proposed 1/2-helix (26) to pro-
line (Fig. 7A), a residue that should break the -helix struc-
ture. Our in vivo cell-based activity assay shows that this
mutant protein has similar activity as wild-type VKOR (Fig.
7B). Therefore, the proposed 1/2-helix following the con-
served loop cysteines of human VKOR appears not to func-
tion as a control mechanism as proposed for its bacterial
homologue (26).
DISCUSSION
VKOR is an ER membrane protein that reduces KO to vita-
min K and is the target of warfarin. Although the membrane
orientation of the C terminus of VKOR is not in doubt, the
FIGURE 3. In vivo cell-based activity assay of human VKOR and its GFP
fusions used in FPP assay. Human VKOR and its GFP fusions were transiently
expressed in FIXgla-PC/HEK293 cells. Transfected cells were cultured in com-
plete medium containing 5 M KO and 4 M warfarin for 48 h. The concentra-
tion of carboxylated FIXgla-PC in the cell culture medium was measured by
ELISA and normalized by the luciferase activity as described under “Experi-
mental Procedures.” Data are presented as mean  S.D. (n  3).
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number ofmembrane-spanning domains and the orientation of
the N terminus of VKOR have been a source of contention.We
presented a three-TMDmodel derived from in vitro glycosyla-
tion mapping indicating that the N terminus of VKOR is
located in the ER lumen (21). However, a four-TMD model
based on the crystal structure of the bacterial VKOR homo-
FIGURE 4. Selective modification of the endogenous cysteine residues of human VKOR and its C43A/C51A cysteine mutant by mPEG-MAL-5000. A,
C-terminal HPC4-tagged VKOR or its C43A/C51A mutant was transiently expressed in HEK293 cells. Forty eight hours post-transfection, cells were harvested
and permeabilized with digitonin or Triton X-100 before mPEG-MAL modification. Whole cell lysate were applied to SDS-PAGE and transferred to PVDF
membrane; HPC4-tagged VKOR was analyzed by Western blot. B, hydrophobicity profile of VKOR and the location of the endogenous cysteine residues.
Transmembrane regions determined by in vitro translation/co-translocation were marked as TMD1 to TMD3. The putative transmembrane region was marked
as pTMD in gray.
FIGURE 5. FPP topology assay and in vivo cell-based activity assay of charged residue-mutated VKOR. A, FPP topology assay of charged residue-mutated
VKOR, VKOR-CM, as described in the legend to Fig. 2. B, time course of relative fluorescence intensity in FPP assay of GFP fusions of VKOR-CM compared with
the N-terminal GFP fusion of wild-type VKOR. C, cell-based activity assay of charged residue mutated VKOR and its GFP fusions as described in the legend for
Fig. 3.
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logue suggests that the N terminus is located in the cytoplasm
(26). These two topology models of VKOR place the conserved
loop cysteines (Cys-43 and Cys-51) on different sides of the ER
membrane. The location of these loop cysteines is critical for
understanding the mechanism of VKOR. Our objective in this
study is to address the topology and reaction mechanism dis-
crepancy of human VKOR.
To experimentally re-examine the membrane topology of
human VKOR, we used two independent biochemical
approaches to probe the intact VKOR molecule in living cells.
One is a recently established FPP assay that has been success-
fully used for determining the membrane protein topology in
single cells (38). Unlike in vitro translation studies, where ER-
derived microsomes are used as the source of cellular mem-
branes, the FPP assay surveys proteins that are delivered by the
cellular machinery to their correct destination. In addition, all
the VKOR fusions used in this study for the FPP assay are active
as evidenced by results from the cell-based in vivo activity assay.
The other approach is the widely used selective modification of
cysteines in the membrane protein by PEG-MAL (29). We also
extended this selective modification to mammalian cells that
overexpress the functional human VKOR or its cysteine
mutant. Our results from both the FPP assay and selective cys-
teine modification support our previous conclusion that
human VKOR is a three-TMD protein (Figs. 2 and 4).
It is worth noting that selective modification of cysteine res-
idues to define the membrane topology of human VKOR has
also been used in a recent study by Schulman et al. (27). How-
ever, these authors reported results that they interpreted as
supporting the four-TMD model of VKOR. This is the only
direct evidence to support the four-TMD model of human
VKOR. These authors state the following: “Each cysteine mod-
ified by Mal-PEG is expected to increase the molecular weight
of VKOR by 5 kDa.”While explaining their results, they state
the following: “With wild-type VKOR, little modification was
observed. However, extensive modification was observed when
the ER membrane was solubilized with Triton X-100, as
expected from the presence of multiple endogenous cysteines
located inside the ER membrane and in the ER lumen” (27).
Based on the work of Lu et al. (29) and our results (Fig. 4), one
would expect modification of multiple cysteines in a protein to
result in multiple gel bands with different sizes representing
different extents of cysteinemodification, rather than one band
with different intensities (see Fig. 1B in Ref. 27).
In addition, in that study, a cysteine residue was introduced
either into the N terminus (S3C) or the C terminus (G158C) of
VKOR (27). The N-terminal cysteine mutant VKOR (S3C)
modification shows an increased intensity of a PEG-modified
VKOR band after Triton X-100 treatment compared with dig-
itonin treatment (Fig. 1B, compare lane 7with lane 5 in Ref. 27).
With the C-terminal cysteine mutant VKOR (G158C) modifi-
cation, however, the intensity of the PEG-modifiedVKORband
in the sample treated with digitonin is similar to that treated
with Triton X-100 (Fig. 1B, compare lane 9with lane 11 in Ref.
27). If the two cysteines were on the same side of themembrane
as in the four-TMD model, one would expect the same degree
ofmodification for either theN- or C-terminal cysteinemutant
VKORwith digitonin treatment. However, the accessibility and
the relative reactivity of the two added cysteines may be differ-
ent at the N or C terminus. For that reason, it appears that their
results could be interpreted to support the three-TMD as well
as the four-TMD topology model for VKOR.
The main difference between the two proposed topology
models for VKOR is the orientation of the first TMD in the ER
membrane (Fig. 1). It has been shown that the orientation of the
transmembrane helix is primarily determined by the charged
residues flanking the hydrophobic core, the positive inside rule
that applies to both bacterial and mammalian membrane pro-
teins (37, 39), i.e.positively charged residues aremore abundant
on the cytoplasmic side (inside) of membrane proteins as com-
pared with the lumenal/periplasmic side. Because the four-
TMD topologymodel of humanVKOR derives from the crystal
structure of the VKORH of Synechococcus (Syn-VKORH), we
compared the charge distribution flanking TMD1 of human
VKOR and Syn-VKORH. The net charge difference (C-N)
between the C- and N-terminal flanking regions of human
TMD1according to the rules byHartmann et al. (39) is1.5. By
contrast, Syn-VKORH has a net charge difference of 3.5
between the C and N termini of TMD1. Thus, these two pro-
teins have a very different distribution of charged residues
flanking TMD1. According to the positive inside rule, the N
terminus of VKOR should be located in the ER lumen, consist-
ent with the three-TMD model. However, the N terminus of
Syn-VKORH should be located in the cytoplasm, which agrees
with the four-TMD topology model derived from its crystal
structure. The overall charge distribution of these two proteins
in their own topology model is consistent with the positive
inside rule (Fig. 8A). If VKOR had four TMDs as proposed
from its bacterial homologue, the charged residue distribution
flanking TMD1 and the putative TMD2 would violate the pos-
itive inside rule (Fig. 8B). Therefore, deduction of the mem-
brane topology of human VKOR from its bacterial VKORH
may not be appropriate.
FIGURE 6. In vivo cell-based activity assay of the cysteine mutants of
human VKOR and VKOR-CM. Cysteine mutants of VKOR or VKOR-CM were
transiently expressed in FIXgla-PC/HEK293 cells, and the enzymatic activity
was determined as described in the legend to Fig. 3.
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It has been shown that mutating the charged residues flank-
ing a signal sequence can invert the orientation of the peptide in
themembrane (40). To further test the contribution of the pos-
itive inside rule in VKOR topology, we made charged residue
mutations around the first TMD of human VKOR (VKOR-
CM). The topology prediction programTMHMMpredicts that
themembrane orientation of TMD1has been inverted, and this
VKOR-CMmutant has been changed to a four-TMDmolecule
with the C-terminal half of the molecule staying the same as in
the three-TMD form. FPP assays confirmed that VKOR-CM
has both the N and C terminus facing to the cytoplasm. Inter-
estingly, this molecule is even more active than the wild-type
enzyme. One possible explanation for the increased activity in
the four-TMD human VKOR-CM is that changing the orienta-
tion of TMD1 may change the warfarin sensitivity of VKOR.
Several residues responsible for warfarin resistance have been
identified in the loop region following TMD1. These residues
are located in the cytoplasm of the wild-type enzyme, but they
are located in the ER lumen in the VKOR-CM mutant. This
topological differencemay alter warfarin sensitivity resulting in
an apparent increase in VKOR activity because we include war-
farin in the cell culture medium of our cell-based activity assay
to inactivate the endogenous VKOR.
The other major difference in our data compared with other
publications concerns the role of the loop cysteines. The loop
cysteines are conserved essentially over all the known VKOR
molecules. Thus, there seems little doubt that they serve an
important function. It is clear that the role of the conserved
loop cysteines in bacterial VKORH is to transfer electrons to
the active site cysteines (24–26). Because of the homology
FIGURE 7. In vivo cell-based activity assay of human VKOR and its V54P mutant. A, sequence alignment of VKORs from different species per Ref. 26.
Sequences were truncated between TMD1 and TMD2 as in the four-TMD topology model. Conserved loop cysteines and conserved serine are highlighted in
gray. The conserved valine in the middle of the 1/2-helix is boxed. The numbers at the top refer to the position of amino acid residues in the human VKOR
sequence. B, human VKOR and its V54P mutant were transiently expressed in FIXgla-PC/HEK293 cells, and the enzymatic activity was determined as described
in the legend to Fig. 3.
FIGURE 8. Charge distribution of human VKOR and Syn-VKORH in the proposed topology models. A, net charge distribution in the three-TMD model of
human VKOR and the four-TMD model of the VKOR domain of Syn-VKORH. Net charges of the loops and the termini are calculated according to the rules by
Hartmann et al. (39) and are indicated inside the circle. Arginine, lysine, and the N-terminal amino group were given a value of 1, histidine 0.5, and aspartate
and glutamate 1 as described previously. B, net charge distribution in the proposed four-TMD model of human VKOR. The putative TMD that functions as an
authentic TMD in the four-TMD variant is shown in light gray with dotted line.
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between human and bacterial VKORs, it was reasonable to
assume that the corresponding loop cysteines, Cys-43 and
Cys-51 of human VKOR, have a similar function as VKORH in
bacteria.
Nevertheless, biochemical data suggest that the two con-
served loop cysteines are not required for human VKOR activ-
ity (16, 18). These results agree with the three-TMD model
because the loop cysteine and the active site are located at the
opposite side of the ER membrane. These earlier studies were
based on the in vitroVKOR activity assay that usedDTT, which
could bypass the role of the endogenous reductant. Recently,
experiments using a cell-based assay, where VKOR uses its
endogenous reductant, showed that the loop cysteines are not
required for VKOR activity (20). Even when the loop cysteines
are located on the same side of the ER membrane as the active
site cysteines (Fig. 6, VKOR-CM), these two cysteines appear
not to be involved in VKOR activity. Interestingly, the Myco-
bacterium tuberculosisVKOR homologue has four TMDs in its
VKOR domain with its loop cysteines located in the periplasm.
These loop cysteines are clearly required for complementation
of DsbB in E. coli (25) but are not essential for its function in
reducing vitamin K or KO in mammalian cells (20). Therefore,
the conserved loop cysteines in VKOR appear not to be
required for the reduction of KO in the vitamin K cycle.
Based on the crystal structure of a bacterial VKORH, it has
been proposed that in humanVKOR there is a “1/2-segment” in
the region of the conserved loop cysteines and a “1/2-helix”
immediately after this segment (Fig. 7A) (26). The 1/2-helix is
proposed to serve as a control mechanism to protect the
enzyme-active site. Results from this study (Fig. 7) and our
previous study (16) show that deleting part of the proposed
1/2-segment or disrupting the proposed 1/2-helix has only a
minor effect on VKOR activity, and this suggests that human
VKOR and its bacterial homologue have different reaction
mechanisms.
In conclusion, we studied the membrane topology of human
VKOR by two independent approaches in mammalian cells.
Our results support the three-TMD topology model of VKOR,
which is consistent with the positive inside rule. We have
shown that VKOR topology can be changed by changing the
charged residue distribution flanking the first TMD. Cell-based
in vivo activity assays show that the conserved loop cysteines
are not essential for VKOR activity, whether they are located in
the cytoplasm or the ER lumen. Together, our results indicate
that human VKOR and its bacterial homologues have different
membrane topologies and different mechanisms for electron
transfer.
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